

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/INTIMATION/2023-24

Date: August 01, 2023

**BSE Limited**

Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra Kurla Complex  
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

**Subject: Intimation under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

Pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ('the Company') is scheduled to be held on Tuesday, August 08, 2023 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to inter-alia, consider and approve the following business(s):

1. The Un-audited Financial Results of the Company (Standalone and Consolidated) for the quarter ended on June 30, 2023.
2. To consider & approve draft Annual Report for the financial year 2022-23.
3. To re-appoint Ms. Sumita Dwivedi (DIN 08218640) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
4. To re-appoint Ms. Sangeeta Bishnoi (DIN 08288998) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
5. To re-appoint Mr. Arun Kumar (DIN: 07031730) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
6. To re-appoint Dr. Ravi Kumar Bansal (DIN: 08462513) as Non-Executive Independent Director of the Company subject to the approval of shareholders in the ensuing General Meeting of the Company.
7. Any other business with the permission of the chair.

It was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the April 01, 2023 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.

This is for your information and record.

Yours faithfully

**for Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary & Compliance Officer**